Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.

1 January 1998.

van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, Schoemaker RC, Cohen AF

The removal of recombinant tissue-type plasminogen activator (rt-PA; alteplase) by the liver is so rapid that liver blood flow becomes rate determining for its clearance. In patients with myocardial infarction changes in liver blood flow may result from impaired cardiac performance or drug treatment.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact

Therapeutic Areas

challenges

methods

Trial Services

Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.

Advancing the boundaries of clinical drug development